HLA-A and neoplasm: Regardless of the treatment arm, low tumor-specific HLA-A expression (<80%) was associated with decreased PFS (carboplatin, HR = 1.90; 95% CI, 0.97-3.69; combination, HR = 1.56, 95% CI, 0.81-2.97) (Figure 5).